Portfolio

1 | 2 | 3 | 4

CombinatoRx (NASDAQ:CRXX)

CombinatoRx is a Cambridge, MA-based biopharmaceutical company that established the new field of combination pharmaceuticals – synergistic combinations of approved drugs. Formed in 2000, the company’s IPO was in 2005.

Cylene Pharmaceuticals

» www.cylenepharma.com

Cylene Pharmaceuticals is developing targeted small molecule drugs to treat drug-resistant forms of life-threatening cancers. The San Diego-based company has multiple product candidates in different phases of development, including Quarfloxin (CX-3543), a Ribosomal RNA Biogenesis Inhibitor (RBI) in late Phase I clinical development.

Enanta Pharmaceuticals, Inc.

» www.enanta.com

Enanta Pharmaceuticals is a research and development company focused on developing best-in-class small molecule drugs in the anti-infective field through the application of innovative chemistry. By integrating chemistry with biology the company has created Bicyclolides, a new class of macrolide antibiotics that overcome bacterial resistance and has additional programs in the anti-viral area targeted at treating Hepatitis C. Enanta is based in Watertown, MA.

GulfStream Bioinformatics

» www.ardais.com

GulfStream Bioinformatics (formerly Ardais), based in Lexington, MA, creates comprehensive web-based software solutions for biomedical research and drug development. The company’s flagship product is BIGR™, (Biomaterials and Information for Genomics Research), which facilitates biospecimen management.

1 | 2 | 3 | 4

"As a CEO, I value both BioVentures Investors' experience in building shareholder value and their background as founders and advisors to emerging companies."

Peter Vitulli
President & CEO
Sciona

» Read Success Story

"BioVentures Investors brings a wealth of operating experience and scientific knowledge."

Stella M. Sung, Ph.D.
Chief Business Officer
Cylene Pharmaceuticals

» Read Success Story

"I'd call BioVentures Investors a 'user-friendly' venture capital firm. They understand technology development timelines and the issues related to medical devices."

Steven J. Tallarida
President Spirus Medical and ,
Founder AngioLink Corporation.

» Read Success Story

"What really sets them apart is their maturity, their understanding of the whole world of start-ups and what it takes to get a new idea and technology off the ground."

James Lousararian
President & CEO
Verax Biomedical

» Read Success Story